Zentalis Pharma has shelved its oral SERD and EGFR inhibitors due to competition and focused on ZN-c3, an inhibitor of WEE1. AZN left the WEE1 space last year, which is a cause for both worry and ...

Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 Uterine serous carcinoma (USC) is a distinct ...

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the ...

Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suitedDOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea ...

Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitorEmergi ...

DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that ...

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that new ...

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- HUYABIO International, the leader in accelerating global development of China's pharmaceutical innovations, announced today it had licensed exclusive worldwide ...

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts Thirty-four patients with locally advanced ...

MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has ...